Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling

BACKGROUND: Abnormal B-cell activation is implicated in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus (SLE). The B-cell surface molecule CD22, which regulates activation through the B-cell receptor (BCR), is a potential target for inhibiting pathogenic B cells; howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Giltiay, Natalia V., Shu, Geraldine L., Shock, Anthony, Clark, Edward A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433084/
https://www.ncbi.nlm.nih.gov/pubmed/28506291
http://dx.doi.org/10.1186/s13075-017-1284-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433084/
https://www.ncbi.nlm.nih.gov/pubmed/28506291
http://dx.doi.org/10.1186/s13075-017-1284-2

Ejemplares similares